133 related articles for article (PubMed ID: 15900429)
1. Does the imaging method have an influence on the measured tumor height in ruthenium plaque therapy of uveal melanoma?
Schueller P; Dogan A; Panke JE; Micke O; Willich N
Strahlenther Onkol; 2005 May; 181(5):320-5. PubMed ID: 15900429
[TBL] [Abstract][Full Text] [Related]
2. Ruthenium brachytherapy for uveal melanoma, 1979-2003: survival and functional outcomes in the Swedish population.
Bergman L; Nilsson B; Lundell G; Lundell M; Seregard S
Ophthalmology; 2005 May; 112(5):834-40. PubMed ID: 15878063
[TBL] [Abstract][Full Text] [Related]
3. Pigmented episcleral deposits after brachytherapy of uveal melanoma.
Toivonen P; Kivelä T
Ophthalmology; 2006 May; 113(5):865-73. PubMed ID: 16530837
[TBL] [Abstract][Full Text] [Related]
4. Ruthenium-106 plaque brachytherapy for thick posterior uveal melanomas.
Kaiserman N; Kaiserman I; Hendler K; Frenkel S; Pe'er J
Br J Ophthalmol; 2009 Sep; 93(9):1167-71. PubMed ID: 19570767
[TBL] [Abstract][Full Text] [Related]
5. Proton therapy of uveal melanomas: intercomparison of MRI-based and conventional treatment planning.
Marnitz S; Cordini D; Bendl R; Lemke AJ; Heufelder J; Simiantonakis I; Kluge H; Bechrakis NE; Foerster MH; Hinkelbein W
Strahlenther Onkol; 2006 Jul; 182(7):395-9. PubMed ID: 16826358
[TBL] [Abstract][Full Text] [Related]
6. A histologic study (including DNA quantification and Ki-67 labeling index) in uveal melanomas after brachytherapy with ruthenium plaques.
Schilling H; Sehu KW; Lee WR
Invest Ophthalmol Vis Sci; 1997 Sep; 38(10):2081-92. PubMed ID: 9331272
[TBL] [Abstract][Full Text] [Related]
7. [Criteria for assessing the efficacy of brachytherapy of uveal melanomas, complications of therapy and there prevention].
Brovkina AF; Zarubeí GD; Val'skií VV
Vestn Oftalmol; 1997; 113(3):14-6. PubMed ID: 9265351
[TBL] [Abstract][Full Text] [Related]
8. Effect of radiation dose on ocular complications after iodine brachytherapy for large uveal melanoma: empirical data and simulation of collimating plaques.
Puusaari I; Heikkonen J; Kivelä T
Invest Ophthalmol Vis Sci; 2004 Oct; 45(10):3425-34. PubMed ID: 15452045
[TBL] [Abstract][Full Text] [Related]
9. Regression of uveal melanoma after ru-106 brachytherapy and thermotherapy based on metabolic activity measured by positron emission tomography/computed tomography.
Lee CS; Lee SC; Lee K; Kwon HJ; Yi JH; Cho A
Retina; 2014 Jan; 34(1):182-7. PubMed ID: 23719400
[TBL] [Abstract][Full Text] [Related]
10. Disease control and toxicity outcomes using ruthenium eye plaque brachytherapy in the treatment of uveal melanoma.
Takiar V; Gombos DS; Mourtada F; Rechner LA; Lawyer AA; Morrison WH; Garden AS; Beadle BM
Pract Radiat Oncol; 2014; 4(4):e189-94. PubMed ID: 25012839
[TBL] [Abstract][Full Text] [Related]
11. Ultrasonic mirror image from ruthenium plaque facilitates calculation of uveal melanoma treatment dose.
Espensen CA; Jensen PK; Fog LS; Appelt AL; Klemp K; Fledelius HC; Specht L; Kiilgaard JF
Br J Ophthalmol; 2017 Sep; 101(9):1206-1210. PubMed ID: 28159770
[TBL] [Abstract][Full Text] [Related]
12. Changes in ultrasound findings in posterior uveal melanoma after Ruthenium 106 brachytherapy.
Kaiserman I; Anteby I; Chowers I; Blumenthal EZ; Kliers I; Pe'er J
Ophthalmology; 2002 Jun; 109(6):1137-41. PubMed ID: 12045056
[TBL] [Abstract][Full Text] [Related]
13. Panophthalmitis with acute scleral necrosis after brachytherapy of a malignant melanoma of the ciliary body.
Bodanowitz S; Strempel I; Wiegand W; Kroll P
Ger J Ophthalmol; 1995 Nov; 4(6):380-2. PubMed ID: 8751105
[TBL] [Abstract][Full Text] [Related]
14. Visual acuity after Ruthenium(106) brachytherapy of choroidal melanomas.
Damato B; Patel I; Campbell IR; Mayles HM; Errington RD
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):392-400. PubMed ID: 15990248
[TBL] [Abstract][Full Text] [Related]
15. Iris and anterior chamber angle neovascularization after iodine 125 brachytherapy for uveal melanoma.
Detorakis ET; Engstrom RE; Wallace R; Straatsma BR
Ophthalmology; 2005 Mar; 112(3):505-10. PubMed ID: 15745782
[TBL] [Abstract][Full Text] [Related]
16. Radiotherapy of liver metastases. Comparison of target volumes and dose-volume histograms employing CT- or MRI-based treatment planning.
Pech M; Mohnike K; Wieners G; Bialek E; Dudeck O; Seidensticker M; Peters N; Wust P; Gademann G; Ricke J
Strahlenther Onkol; 2008 May; 184(5):256-61. PubMed ID: 18427756
[TBL] [Abstract][Full Text] [Related]
17. Local tumor control after 106Ru brachytherapy of choroidal melanoma.
Damato B; Patel I; Campbell IR; Mayles HM; Errington RD
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):385-91. PubMed ID: 15913907
[TBL] [Abstract][Full Text] [Related]
18. Ruthenium plaque radiation for iris and iridociliary melanomas: development of dry eyes?
Razzaq L; de Keizer RJ
Br J Ophthalmol; 2010 Nov; 94(11):1549-50. PubMed ID: 20516146
[No Abstract] [Full Text] [Related]
19. Corneoscleral necrosis after episcleral Au-198 brachytherapy of uveal melanoma.
Chaudhry IA; Liu M; Shamsi FA; Arat YO; Shetlar DJ; Boniuk M
Retina; 2009 Jan; 29(1):73-9. PubMed ID: 18728617
[TBL] [Abstract][Full Text] [Related]
20. Early invasive cervical cancer: tumor delineation by magnetic resonance imaging, computed tomography, and clinical examination, verified by pathologic results, in the ACRIN 6651/GOG 183 Intergroup Study.
Mitchell DG; Snyder B; Coakley F; Reinhold C; Thomas G; Amendola M; Schwartz LH; Woodward P; Pannu H; Hricak H
J Clin Oncol; 2006 Dec; 24(36):5687-94. PubMed ID: 17179104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
